AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR)Trial

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Researchers are comparing two drug therapy plans to treat heart function changes after anthracycline-based treatment for lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Carvedilol; Lisinopril; Pravastatin; Spironolactone

Criteria

Inclusion criteria:

• ≥18 years of age,

• New diagnosis of reduced cardiac function

• Prior anthracycline-based cancer therapy for lymphoma

Exclusion criteria:

• History of HF of any class and type, or diagnosis of cardiomyopathy prior to anthracycline therapy

• On active therapy with a fibrate, niacin, or eplerenone

• History of myopathy/rhabdomyolysis

• History of statin intolerance

• Active hyperlipidemia

• History of gout

• Active liver disease

• Unexplained persistent elevations of serum transaminases

• Pregnancy

• Breast-feeding

• Hyperkalemia

• Addison disease

• eGFR <30 mL/minute/1.73 m2